Moreover, by monitoring mice for a longer time, we observed that at day 124, the tumor free survival was 64% in the L19-IL2/OC-46F2 high dose group compared to 0% observed in L19-IL2 treated group. The gene discussed is IL2; the disease is neoplasm.